Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus SYMBICORT AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus SYMBICORT AEROSPHERE.
AZMACORT vs SYMBICORT AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Budesonide is a corticosteroid with anti-inflammatory activity; its mechanism includes inhibition of multiple inflammatory cell types and mediators. Formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
Two inhalations (budesonide 160 mcg/formoterol 4.5 mcg per inhalation) twice daily (morning and evening). Maximum dose: 2 inhalations twice daily.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Budesonide: 2-3 hours. Formoterol: 10-14 hours. Clinically, twice-daily dosing maintains effect due to active metabolite accumulation.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Budesonide: 60% renal metabolites, 40% fecal. Formoterol: 60% renal, 40% fecal via biliary, with 10% unchanged drug.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist